[I-131]MIBG and topotecan: A rationale for combination therapy for neuroblastoma

McCluskey, A., Boyd, M., Gaze, M. and Mairs, R. (2005) [I-131]MIBG and topotecan: A rationale for combination therapy for neuroblastoma. Cancer Letters, 228(1-2), pp. 221-227. (doi: 10.1016/j.canlet.2005.11.062)

Full text not currently available from Enlighten.


MIBG is selectively concentrated in neuroblastoma cells, and radioiodinated MIBG has been used with some success for targeted radiotherapy. However, long-term cure remains elusive, and the topoisomerase I inhibitor topotecan may improve upon existing [I-131]MIBG therapy. While synergistic killing by combinations of ionising radiation and topoisomerase I inhibitors has been reported, there is no consensus on optimal scheduling. Furthermore, there has been no attempt to demonstrate radiopotentiation by topoisomerase I inhibitors and targeted radiotherapy. We are investigating various scheduled combinations of topotecan and [I-131]MIBG on neuroblastoma cells, and preliminary data suggests that topotecan induces increased accumulation of [I-131]MIBG in vitro.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Mairs, Professor Robert and Boyd, Dr Marie
Authors: McCluskey, A., Boyd, M., Gaze, M., and Mairs, R.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:Cancer Letters

University Staff: Request a correction | Enlighten Editors: Update this record